title: Impact of the new American and British guidelines on the management and treatment of dyslipidemia in a Spanish working population.
abstract: OBJECTIVE
  The guidelines of the American College of Cardiology/American Heart Association and the British National Institute for Health and Clinical Excellence on the management and treatment of dyslipidemia recommend significant changes, such as the abolition of therapeutic targets and the use of new risk tables. This study aimed to evaluate the impact of the use of these new guidelines compared with the application of European guidelines.
  
  
  METHODS
  Observational study conducted among Spanish workers. We included all workers registered with the Sociedad de Prevención de Ibermutuamur in 2011 whose cardiovascular risk could be evaluated. Cardiovascular risk was calculated for each worker using the Systematic Coronary Risk Evaluation cardiovascular risk tables for low-risk countries, as well as the tables recommended by the American and British guidelines.
  
  
  RESULTS
  A total of 258,676 workers were included (68.2% men; mean age, 39.3 years). High risk was found in 3.74% of the population according to the Systematic Coronary Risk Evaluation tables and in 6.85% and 20.83% according to the British and American tables, respectively. Treatment would be needed in 20 558 workers according to the American guidelines and in 13,222 according to the British guidelines, but in only 2612 according to the European guidelines. By following the American guidelines, the cost of statins would increase by a factor of 8.
  
  
  CONCLUSIONS
  The new recommendations would result in identifying more high-risk patients and in treating a larger fraction of the population with lipid-lowering drugs than with the European recommendations, which would result in increased costs.
authors.affiliation: Unidad de Investigación, Equip d'Atenció Primària Sardenya, Instituto de Investigación Biomédica Sant Pau (IIB-Sant Pau), Barcelona, Spain; Unidad Docente ACEBA, Barcelona, Spain. Electronic address: cbrotons@eapsardenya.cat.
authors.forename: Carlos
authors.initials: C
authors.lastname: Brotons
authors.affiliation: Ibermutuamur, Madrid, Spain.
authors.forename: Eva
authors.initials: E
authors.lastname: Calvo-Bonacho
authors.affiliation: Unidad de Investigación, Equip d'Atenció Primària Sardenya, Instituto de Investigación Biomédica Sant Pau (IIB-Sant Pau), Barcelona, Spain; Unidad Docente ACEBA, Barcelona, Spain.
authors.forename: Irene
authors.initials: I
authors.lastname: Moral
authors.affiliation: Sociedad de Prevención de Ibermutuamur, Madrid, Spain.
authors.forename: María Teresa
authors.initials: MT
authors.lastname: García-Margallo
authors.affiliation: Sociedad de Prevención de Ibermutuamur, Madrid, Spain.
authors.forename: María Victoria
authors.initials: MV
authors.lastname: Cortés-Arcas
authors.affiliation: Unidad de Investigación, Equip d'Atenció Primària Sardenya, Instituto de Investigación Biomédica Sant Pau (IIB-Sant Pau), Barcelona, Spain; Unidad Docente ACEBA, Barcelona, Spain.
authors.forename: Mireia
authors.initials: M
authors.lastname: Puig
authors.affiliation: Unidad de Investigación, Equip d'Atenció Primària Sardenya, Instituto de Investigación Biomédica Sant Pau (IIB-Sant Pau), Barcelona, Spain; Unidad Docente ACEBA, Barcelona, Spain.
authors.forename: Gastón
authors.initials: G
authors.lastname: Vázquez-Pirillo
authors.affiliation: Instituto de Investigación, Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: Luis Miguel
authors.initials: LM
authors.lastname: Ruilope
mesh_terms: D000328:Adult; D003327:Coronary Disease / Q000517:prevention & control; D050171:Dyslipidemias / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D013030:Spain
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents
keywords: Cardiovascular diseases; Cardiovascular drugs; Clinical practice guidelines; Enfermedades cardiovasculares; Fármacos cardiovasculares; Guía de práctica clínica